Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: A randomized placebo-controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Capasso, Immacolata ^a   Esposito, Emanuela ^a   Maurea, Nicola ^a   Montella, Maurizio ^a   Crispo, Anna ^a   De Laurentiis, Michelino ^a   D'Aiuto, Massimiliano ^a   Frasci, Giuseppe ^a   Botti, Gerardo ^a   Grimaldi, Maria ^a   Cavalcanti, Ernesta ^a   Esposito, Giuseppe ^a   Fucito, Alfredo ^a   Brillante, Giuseppe ^a   D'Aiuto, Giuseppe ^a   Ciliberto, Gennaro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Alpha lipoic acid; Breast cancer; HDL cholesterol; Inositol; Insulin resistance; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL; INSULIN; THIOCTIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW CALORY DIET; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; POSTMENOPAUSE; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; BREAST NEOPLASMS; CALORIC RESTRICTION; CHOLESTEROL, HDL; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INOSITOL; INSULIN; INSULIN RESISTANCE; ITALY; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; THIOCTIC ACID; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 84883076717     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-273     Document Type: Article

References (15)

1. Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, De Marco M, Cavalcanti E, D'Aiuto M, Fucito A, Frasci G, Maurea N, Esposito G, Pedicini T, Vecchione A, D'Aiuto G, Giordano A. Metabolic syndrome affects breast cancer risk in postmenopausal women National Cancer Institute of Naples experience. Cancer Biol Ther 2010, 10:1240-1243. 10.4161/cbt.10.12.13473, 20935521.
2. Capasso I, Esposito E, Pentimalli F, Montella M, Crispo A, Maurea N, D' Aiuto M, Fucito A, Grimaldi M, Cavalcanti E, Esposito G, Brillante G, Lodato S, Pedicini T, D' Aiuto G, Ciliberto G, Giordano A. Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience. J Exp Clin Cancer Res 2013, 32:14. [Epub ahead of print], 10.1186/1756-9966-32-14, 3622613, 23497533.
3. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, Krogh V. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010, 20:41-48. Epub 2009 Apr 10, 10.1016/j.numecd.2009.02.006, 2819536, 19361966.
4. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE. Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes 2004, 53:2087-2094. 10.2337/diabetes.53.8.2087, 15277390.
5. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, Neuhouser ML, Parker DR, Shikany JM, Stefanick ML, Thomson CA, Rohan TE. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:2046-2053. Epub 2009 Jun 30, 10.1158/1055-9965.EPI-09-0235, 19567502.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Executive summary of the third report of the National Cholesterol Education Program (NCEP).
7. Stebbing J, Sharma A, North B, Athersuch TJ, Zebrowski A, Pchejetski D, Coombes RC, Nicholson JK, Keun HC. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol 2012, 23:860-866. Epub 2011 Aug, 10.1093/annonc/mdr347, 21821546.
8. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011, 126:215-220. Epub 2010 Oct 26, 10.1007/s10549-010-1224-1, 20976543.
9. Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev 2010, 29:751-759. 10.1007/s10555-010-9261-0, 20922461.
10. Saltiel AR. Second messengers of insulin action. Diabetes Care 1990, 13:244-256. 10.2337/diacare.13.3.244, 2137771.
11. Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, Di Benedetto A, D'Anna R. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause 2011, 18:102-104. 10.1097/gme.0b013e3181e8e1b1, 20811299.
12. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008, 24:139-144. 10.1080/09513590801893232, 18335328.
13. Sample Size Calculator. http://www.surveysystem.com/sscalc.htm.
14. American Diabetes Association Standards of medical care in diabetes-2012. Diabetes Care 2012, Suppl 1:S11-S63. American Diabetes Association.
15. Pfeiler G, Treeck O, Wenzel G, Goerse R, Hartmann A, Schmitz G, Ortmann O. Influence of insulin resistance on adiponectin receptor expression in breast cancer. Maturitas 2009, 63:253-256. Epub 2009 Jun 13, 10.1016/j.maturitas.2009.04.006, 19524379.